Results 151 to 160 of about 2,147 (178)
Some of the next articles are maybe not open access.
What is rilonacept's role in treating recurrent pericarditis?
JAAPA, 2022ABSTRACT The interleukin (IL)-1 antagonist rilonacept is approved by the FDA to treat recurrent pericarditis. In adults and adolescents with multiple recurrences of pericarditis, compared with placebo, rilonacept is associated with a lower risk of recurrent pericarditis, more persistent clinical response, normalized C-reactive protein within ...
openaire +2 more sources
Rilonacept in the treatment of chronic inflammatory disorders
Drugs of Today, 2009Rilonacept (IL-1 Trap/Arcalyst) is a long-acting interleukin-1 (IL-1) blocker developed by Regeneron Pharmaceuticals. Initially, Regeneron entered into a joint development effort with Novartis to develop rilonacept for the treatment of rheumatoid arthritis (RA) but this was discontinued following the review of phase II clinical data showing that IL-1 ...
openaire +2 more sources
Annals of the New York Academy of Sciences, 2010
Rilonacept is a dimeric fusion protein consisting of the extracellular domains of interleukin (IL)-1 type 1 receptor and IL-1 receptor accessory protein joined to the constant region (Fc) of human immunoglobulin G1. By incorporating both components of the IL-1 binding complex, rilonacept is able to tightly bind IL-1 with picomolar affinity.
Neil, Stahl, Allen, Radin, Scott, Mellis
openaire +1 more source
Rilonacept is a dimeric fusion protein consisting of the extracellular domains of interleukin (IL)-1 type 1 receptor and IL-1 receptor accessory protein joined to the constant region (Fc) of human immunoglobulin G1. By incorporating both components of the IL-1 binding complex, rilonacept is able to tightly bind IL-1 with picomolar affinity.
Neil, Stahl, Allen, Radin, Scott, Mellis
openaire +1 more source
New drugs: Methylnaltrexone bromide, alvimopan, and rilonacept
Journal of the American Pharmacists Association, 2008Agent for opioid-induced constipation Each year, an estimated 1.5 million Americans are treated with an opioid analgesic (e.g., morphine) on a continuous basis to relieve pain associated with incurable cancers, end-stage chronic obstructive pulmonary disease from emphysema, heart failure, and other advanced illnesses.
openaire +2 more sources
Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever
Annals of Internal Medicine, 2012Currently, there is no proven alternative therapy for patients with familial Mediterranean fever (FMF) that is resistant to or intolerant of colchicine. Interleukin-1 is a key proinflammatory cytokine in FMF.To assess the efficacy and safety of rilonacept, an interleukin-1 decoy receptor, in treating patients with colchicine-resistant or -intolerant ...
Philip J, Hashkes +13 more
openaire +2 more sources
The IL-1 trap rilonacept resolves and prevents recurrent pericarditis
Nature Reviews Cardiology, 2020In patients with recurrent pericarditis, treatment with rilonacept, an engineered fusion protein that acts as an IL-1 trap, leads to a rapid resolution of recurrent pericarditis episodes and reduces the risk of pericarditis recurrence.
openaire +2 more sources
Real-life experience with rilonacept for the treatment of recurrent pericarditis
European Heart JournalAbstract Background Rilonacept, a soluble Interleukin-1 (IL-1) receptor fusion protein that neutralizes IL-1α and IL-1β, has shown efficacy in symptom resolution, weaning of standard-of-care therapies, and reducing the frequency of recurrent pericarditis (RP) episodes in clinical trials.
G Thomas +3 more
openaire +1 more source
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis
Annals of Pharmacotherapy, 2022Nicholas Schwier
exaly
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease
Expert Opinion on Biological Therapy, 2022Lucia, Trotta +9 more
openaire +2 more sources
Rilonacept for familial Mediterranean fever?
Nature Reviews Rheumatology, 2012openaire +1 more source